menu
    • menu

    Company profile for D3 Bio

    NEW Drugs in Dev: 5
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    D3 Bio is a biotechnology firm with a global scope, dedicated to the development and registration of cutting-edge medicines in the fields of oncology and immunology. Our approach to new medicine development sets us apart. Rather than solely beginning with scientific research in the lab, we first identify the most pressing unmet needs of patients and the market. We focus on areas where current standard-of-care treatments fail t...
    D3 Bio is a biotechnology firm with a global scope, dedicated to the development and registration of cutting-edge medicines in the fields of oncology and immunology. Our approach to new medicine development sets us apart. Rather than solely beginning with scientific research in the lab, we first identify the most pressing unmet needs of patients and the market. We focus on areas where current standard-of-care treatments fail to deliver satisfactory clinical outcomes.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    D3 BioChina Flag
    Country
    Country
    China
    Address
    Address
    324 (Room 324), 88 MeiLiang Road, MaShan Street, Binhu District, Wuxi (and Sha...
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.d3bio.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    euroPLX 90 Lisbon

    Not Confirmed

    envelop Contact Supplier

    euroPLX 90 Lisbon

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA Approves D3 Bio INDs for D3S-003 Phase 1, Elisrasib-D3S-002
    FDA Approves D3 Bio INDs for D3S-003 Phase 1, Elisrasib-D3S-002

    18 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/d3-bio-receives-us-fda-clearance-for-two-ind-applications-enabling-phase-1-trial-of-d3s003-and-phase-2-combination-study-of-elisrasib-d3s001-with-d3s002-302664022.html

    PR NEWSWIRE
    18 Jan 2026
    Share Share
    D3 Bio Secures $108M Series B for Global Clinical Trials Program
    D3 Bio Secures $108M Series B for Global Clinical Trials Program

    10 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/d3-bio-secures-108-million-in-series-b-financing-to-advance-global-clinical-programs-302636690.html

    PR NEWSWIRE
    10 Dec 2025
    Share Share
    D3 Bio Gets FDA BTD & ODD Designation for D3S-001 in Cancers
    D3 Bio Gets FDA BTD & ODD Designation for D3S-001 in Cancers

    28 Aug 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/d3-bio-inc-announces-fda-breakthrough-therapy-designation-and-orphan-drug-designation-for-d3s-001-for-the-treatment-of-patients-with-kras-g12c-mutated-cancers-302540808.html

    PR NEWSWIRE
    28 Aug 2025
    Share Share
    D3 Bio Announces Nature Medicine Publication & Present at AACR 2025
    D3 Bio Announces Nature Medicine Publication & Present at AACR 2025

    29 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250429337560/en/D3-Bio-Announces-Nature-Medicine-Publication-and-AACR-2025-Presentation-Highlighting-D3S-001-as-a-Next-Generation-KRAS-G12C-Inhibitor-with-Best-in-Class-Potential

    BUSINESSWIRE
    29 Apr 2025
    Share Share
    D3 Bio’s D3S-001 Shows Potent KRAS Depletion in Pre-Clinical Studies
    D3 Bio’s D3S-001 Shows Potent KRAS Depletion in Pre-Clinical Studies

    25 Nov 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241125088779/en

    BUSINESSWIRE
    25 Nov 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search